Below are the most recent publications written about "Inflammatory Bowel Diseases" by people in Profiles.
-
Agrawal A, Chopra S, Bhagat U, Banga A, Rosenzveig A, Arockiam AD, Rahman SU, Patel R, Ganatra S, Dani SS. Racial and Sex Disparities in Patients With Takotsubo Cardiomyopathy With Inflammatory Bowel Disease. Heart Lung Circ. 2026 May; 35(5):696-703.
-
Kurapati S, Shin C, Szabo K, Liu Y, Ashraf AZ, Koscso B, Dash C, Kruckow KL, Navarro LE, Clark AM, Saha M, Nagaraj S, Wang W, Zhu J, Brown K, Thomson T, Shulzhenko N, Morgun A, Baer CE, Srinivasan S, Kulkarni S, Pasricha PJ, Peters LA, Bogunovic M. Inflammation rewires the enteric nervous system through neurogenic monocyte recruitment. J Exp Med. 2026 Apr 06; 223(4).
-
Feldman HT, Tejan J, Victoria R, Rupawala A, Soni A. Wearable Technology and Remote Physiological Monitoring in Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2026 Mar 01; 60(3):216-224.
-
Vargas-Robles D, Yap YR, Singha B, Tien J, Purandare M, Rojas-Correa M, Madziar C, Picker M, Dumont T, Leftwich HK, Frisard CF, Ward DV, Peter I, Olendzki B, Maldonado-Contreras A. Association of vaginal IL-4, IL-6, IL-8, IL-17, IFN-?, and dietary intake with IBD status and vaginal microbiota in pregnant individuals. PLoS One. 2026; 21(1):e0335178.
-
Holubar SD, Eisenstein S, Bordeianou LG, Chapman WC, Crowell KT, Davids JS, Hrabe JE, Justiniano CF, Kapadia MR, Kin CJ, Krane MK, Lee EC, Olortegui KS, Poylin V, Saraidaridis JT, Scow JS, Plietz MC. Venous Thromboembolism Prophylaxis Practice Patterns, Outcomes, and Risk Stratification After Surgery for IBD: A National Surgical Quality Improvement Program IBD Collaborative Study. Dis Colon Rectum. 2025 09 01; 68(9):1062-1073.
-
Castagnoli R, Pala F, Subramanian P, Oguz C, Schwarz B, Lim AI, Burns AS, Fontana E, Bosticardo M, Corsino C, Angelova A, Delmonte OM, Kenney H, Riley D, Smith G, Ott de Bruin L, Oikonomou V, Dos Santos Dias L, Fink D, Bohrnsen E, Kimzey CD, Marseglia GL, Alva-Lozada G, Bergerson JRE, Brett A, Brigatti KW, Dimitrova D, Dutmer CM, Freeman AF, Ale H, Holland SM, Licciardi F, Pasic S, Poskitt LE, Potts DE, Dasso JF, Sharapova SO, Strauss KA, Ward BR, Yilmaz M, Kuhns DB, Lionakis MS, Daley SR, Kong HH, Segre JA, Villa A, Pittaluga S, Walter JE, Vujkovic-Cvijin I, Belkaid Y, Notarangelo LD. Immunopathological and microbial signatures of inflammatory bowel disease in partial RAG deficiency. J Exp Med. 2025 Aug 04; 222(8).
-
Jena KK, Mambu J, Boehmer D, Sposito B, Millet V, de Sousa Casal J, Muendlein HI, Spreafico R, Fenouil R, Spinelli L, Wurbel S, Riquier C, Galland F, Naquet P, Chasson L, Elkins M, Mitsialis V, Ketelut-Carneiro N, Bugda Gwilt K, Thiagarajah JR, Ruan HB, Lin Z, Lien E, Shao F, Chou J, Poltorak A, Ordovas-Montanes J, Fitzgerald KA, Snapper SB, Broggi A, Zanoni I. Type III interferons induce pyroptosis in gut epithelial cells and impair mucosal repair. Cell. 2024 Dec 26; 187(26):7533-7550.e23.
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 10 03; 30(10):1776-1787.
-
Krugliak Cleveland N, Ghosh S, Chastek B, Bancroft T, Candela N, Fan T, Umashankar K, Rubin DT. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
-
Nanaware PP, Khan ZN, Clement CC, Shetty M, Mota I, Seltzer ES, Dzieciatkowska M, Gamboni F, D'Alessandro A, Ng C, Nagayama M, Lichti CF, Soni RK, Matei I, Lyden D, Longman R, Lu TT, Wan X, Unanue ER, Stern LJ, Santambrogio L. Role of the afferent lymph as an immunological conduit to analyze tissue antigenic and inflammatory load. Cell Rep. 2024 06 25; 43(6):114311.